Anticoagulant therapy: basic principles, classic approaches and recent developments

Blood Coagul Fibrinolysis. 2012 Sep;23(6):482-93. doi: 10.1097/MBC.0b013e328355c9cb.

Abstract

The standard multipotent anticoagulants (unfractionated and low molecular weight heparins, antagonists of vitamin K) are commonly used for treatment and/or prophylaxis of different thrombotic complications, such as deep vein thrombosis, thrombophilia, pulmonary embolism, myocardial infarction, stroke and so on. Advantages and shortcomings of these anticoagulants are considered. The modern tendencies to use small selective direct inhibitors of thrombin or factor Xa are surveyed. The search of the new targets in the coagulation cascade for development of new promising anticoagulants and improvement in antithrombotic therapy is discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Blood Coagulation / drug effects*
  • Dabigatran
  • Factor Xa / metabolism
  • Factor Xa Inhibitors
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Hirudins / administration & dosage
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Thrombin / antagonists & inhibitors
  • Thrombin / metabolism
  • Thromboembolism / drug therapy*
  • Thromboembolism / physiopathology
  • Thrombophilia / drug therapy*
  • Thrombophilia / physiopathology
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / physiopathology
  • Vitamin K / antagonists & inhibitors
  • Vitamin K / metabolism
  • Warfarin / therapeutic use
  • beta-Alanine / analogs & derivatives
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Benzimidazoles
  • Factor Xa Inhibitors
  • Heparin, Low-Molecular-Weight
  • Hirudins
  • Platelet Aggregation Inhibitors
  • beta-Alanine
  • Vitamin K
  • Warfarin
  • Thrombin
  • Factor Xa
  • Dabigatran